Results 161 to 170 of about 19,810 (255)

Table 1_Dosimetry-guided peptide receptor radionuclide therapy in neuroendocrine tumors: interim safety analysis of the DUONEN trial.docx

Maciej Kolodziej (20384155), Marta Opalinska (15013766), Renata Mikolajczak (22750172), Alicja Hubalewska-Dydejczyk (2951334), Marek Dedecjus (18890677), Aldona Kowalska (2951361), Marek Saracyn (6645818), Piotr Garnuszek (10957131), Izabela Cieszykowska (22750175), Joanna Januszkiewicz-Caulier (22750178), Joanna Dlugosinska (412452), Adam Daniel Durma (22750181), Katarzyna Jozwik-Plebanek (22750184), Adrianna Mroz (22750187), Katarzyna Janiak (22750190), Danuta Gasior-Perczak (22750193), Malgorzata Trofimiuk-Muldner (22750196), Anna Sowa-Staszczak (2951328), Janusz Braziewicz (8362275), Wioletta Lenda-Tracz (22750199), Krzysztof Kacperski (10125629), Anna Budzynska (22750202), Agata Kubik (4710675), Patrycja Pastusiak (18078030), Wioletta Chalewska (22750205), Anna Borkowska (707633), Paulina Cegla (12827609), Agata Walecka-Mazur (22750208), Artur Szczodry (5807339), Grzegorz Kaminski (22750211)   +29 more
openalex   +1 more source

Paving the Way for CCK2R-Targeted Peptide Receptor Radionuclide Therapy with [¹⁷⁷Lu]Lu-DOTA-MGS5 in Patients with Small Cell Lung Cancer. [PDF]

Pharmaceutics
Zavvar TS, Santo G, Gruber L, Kronthaler A, Hagenbuchner J, Skvortsova I, Piro I, Steiger K, Martinovic V, Minasch D, Löffler-Ragg J, di Santo G, Virgolini IJ, von Guggenberg E.   +13 more
europepmc   +1 more source

Peptide receptor radionuclide therapy as a new tool in treatment-refractory sarcoidosis - initial experience in two patients [PDF]

, 2017
Constantin Lapa, Malte Kircher, Heribert Hänscheid, Andreas Schirbel, Götz Ulrich Grigoleit, Erdwine Klinker, Markus Böck, Samuel Samnick, Theo Pelzer, Andreas K. Buck   +9 more
openalex   +1 more source

Dosimetry-guided peptide receptor radionuclide therapy in neuroendocrine tumors: interim safety analysis of the DUONEN trial. [PDF]

Front Endocrinol (Lausanne)
Kolodziej M, Opalinska M, Mikolajczak R, Hubalewska-Dydejczyk A, Dedecjus M, Kowalska A, Saracyn M, Garnuszek P, Cieszykowska I, Januszkiewicz-Caulier J, Dlugosinska J, Durma AD, Jozwik-Plebanek K, Mroz A, Janiak K, Gasior-Perczak D, Trofimiuk-Muldner M, Sowa-Staszczak A, Braziewicz J, Lenda-Tracz W, Kacperski K, Budzynska A, Kubik A, Pastusiak P, Chalewska W, Borkowska A, Cegla P, Walecka-Mazur A, Szczodry A, Kaminski G.   +29 more
europepmc   +1 more source

Guidance on ¹⁷⁷Lu-DOTATATE Peptide Receptor Radionuclide Therapy from the Experience of a Single Nuclear Medicine Division [PDF]

, 2018
Amanda Abbott, Christopher G. Sakellis, Eric Andersen, Yuji Kuzuhara, Lauren Gilbert, Kelly S. Boyle, Matthew H. Kulke, Jennifer A. Chan, Heather A. Jacene, Annick D. Van den Abbeele   +9 more
openalex   +1 more source

Peptide receptor radionuclide therapy in G3 gastroenteropancreatic neuroendocrine tumors: a missed opportunity for European patients? [PDF]

Lancet Reg Health Eur
Panzuto F, Cives M, Strosberg J.
europepmc   +1 more source

PET imaging of urokinase-type plasminogen activator receptor (uPAR) in prostate cancer: current status and future perspectives [PDF]

, 2016

core   +1 more source

Effect of Peptide Receptor Radionuclide Therapy (PRRT) with tandem isotopes – [90Y]Y/[177Lu]Lu-DOTATATE in patients with disseminated neuroendocrine tumours depending on qualification [18F]FDG PET/CT in Polish multicenter experience – do we need [18F]FDG

, 2020
Anna Zemczak, Maciej Kołodziej, Paweł Gut, Leszek Królicki, Beata Kos‐Kudła, Grzegorz Kamiński, Marek Ruchała, Dariusz Pawlak, Jolanta Kunikowska   +8 more
openalex   +2 more sources

Machine Learning Uncovers Novel Predictors of Peptide Receptor Radionuclide Therapy Eligibility in Neuroendocrine Neoplasms. [PDF]

Cancers (Basel)
Sipka G, Farkas I, Bakos A, Maráz A, Mikó ZS, Czékus T, Bukva M, Urbán S, Pávics L, Besenyi Z.   +9 more
europepmc   +1 more source

Peptide receptor radionuclide therapy alone or in combination with temozolomide plus/minus capecitabine in [¹⁸F]FDG-positive metastatic neuroendocrine tumors. [PDF]

Eur J Nucl Med Mol Imaging
di Santo G, Santo G, Wirth L, Kronthaler A, Gastl G, Djanani A, Virgolini IJ.   +6 more
europepmc   +1 more source